Errors in Affiliation, Figure 3, and Supplement 4

No authors listed

Published Erratum

No authors listed. JAMA Oncol. 2023.

. 2023 Apr 1;9(4):574.

doi: 10.1001/jamaoncol.2023.0822.

No abstract available

Erratum for

Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non-Small Cell Lung Cancer: Pooled Analyses of the Phase 3 IMpower130, IMpower132, and IMpower150 Randomized Clinical Trials.
Socinski MA, Jotte RM, Cappuzzo F, Nishio M, Mok TSK, Reck M, Finley GG, Kaul MD, Yu W, Paranthaman N, Bara I, West HJ. Socinski MA, et al. JAMA Oncol. 2023 Apr 1;9(4):527-535. doi: 10.1001/jamaoncol.2022.7711. JAMA Oncol. 2023. PMID: 36795388 Free PMC article.

1. Socinski MA, Jotte RM, Cappuzzo F, et al. . Association of immune-related adverse events with efficacy of atezolizumab in patients with non-small cell lung cancer: pooled analyses of the phase 3 IMpower130, IMpower132, and IMpower150 randomized clinical trials. JAMA Oncol. Published online February 16, 2023. doi:10.1001/jamaoncol.2022.7711 - DOI - PMC - PubMed